Scinovex
review Open AccessTop 1% cited

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

Annals of the Rheumatic Diseases · 2016 · Vol. 76(1) · pp. 17–28
Rabia AgcaS.C. HeslingaSilvia RollefstadMaaike HeslingaIain B. McInnesMike PetersTore K. KvienMaxime DougadosHelga RadnerFabiola AtzeniJette PrimdahlAnna SödergrenSolveig Wållberg JonssonJef van RompayC. ZabalanTerje R. PedersenL. JacobssonKurt de VlamMiguel Á. González‐GayAnne Grete SembGeorge D. KitasYvo M. SmuldersZoltán SzekaneczNaveed SattarDeborah SymmonsMichael T. Nurmohamed
Rheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsAutoimmune and Inflammatory Disorders ResearchMedicinePsoriatic arthritisRheumatismAnkylosing spondylitisRheumatoid arthritisExpert opinionPopulationDiseasePhysical therapyIntensive care medicine

MeSH terms

Adrenal Cortex HormonesAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCardiovascular DiseasesHumansLife StylePhysician's RoleRheumatologyRisk FactorsRisk ManagementSpondylitis, AnkylosingArthritis, PsoriaticAntirheumatic AgentsRisk AssessmentDirective Counseling

Funding

  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Biogen
  • Celgene
  • Celltrion
  • Vrije Universiteit Amsterdam
  • Diakonhjemmet
  • European League Against Rheumatism
Citations
1,297
FWCI
105.08
field-weighted impact
References
173
Percentile
100%
vs. same field & year
Citations per year
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.